You just read:

Surveyed Neurologists are Eager to Prescribe Gilenya, the First Oral Disease-Modifying Agent for MS, But Say They are Held Back by Initial Prescribing Obstacles and Potential Safety/Tolerability Concerns

News provided by

BioTrends Research Group, Inc.

Dec 06, 2010, 08:00 EST